Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1232-1238

  Watanabe, Akiko ^a,b   Nakamura, Koichi ^a   Okudaira, Noriko ^a   Okazaki, Osamu ^a   Sudo, Ken Ichi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BEPRIDIL; BROMOCRIPTINE; BUPIVACAINE; BUPRENORPHINE; CLARITHROMYCIN; CLOZAPINE; CYTOCHROME P450 3A; DELAVIRDINE; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL; MIBEFRADIL; MIDAZOLAM; NEFAZODONE; NICARDIPINE; NIFEDIPINE; PRAZOSIN; SERTRALINE; TESTOSTERONE; TROLEANDOMYCIN; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BLOOD; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; METABOLIC INHIBITION; PRIORITY JOURNAL;

ANIMALS; AUTOMATION; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KINETICS; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NIFEDIPINE; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 34250716928     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015016     Document Type: Article

References (37)

1. Atkinson A, Kenny JR, and Grime K (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637-1647.
2. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
3. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
4. Crespi CL and Stresser DM (2000) Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 44:325-331.
5. Elkader A and Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661-680.
6. Fontana E, Dansette PM, and Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413-454.
7. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650.
8. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
9. Ibrahim RB, Wilson JG, Thorsby ME, and Edwards DJ (2000) Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sci 66:1293-1298.
10. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
11. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140-1146.
12. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
13. Kuhnz W, Hümpel M, Biere H, and Gross D (1996) Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. Eur J Clin Pharmacol 50:231-235.
14. Lim HK, Duczak N, Brougham L, Elliot M, Patel K, and Chan K (2005) Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211-1219.
15. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
16. Ma B, Prueksaritanont T, and Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125-130.
17. Madan A, Usuki E, Burton LA, Ogilvie BW, and Parkinson A (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs, in Drug-Drug Interactions pp 217-294, Marcel Dekker, Inc. New York.
18. Murray M (1997) Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 24:465-470.
19. Naritomi Y, Teramura Y, Terashita S, and Kagayama A (2004) Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet 19: 55-61.
20. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
21. Omar MA and Wilson JP (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36:288-295.
22. Palovaara S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, and Laine K (2000) Effect of an oral contraceptive preparation containing ethynylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol 50:333-337.
23. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, and Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351:1929-1930.
24. Schulz M and Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447-474.
25. Silverman RB (1988) Mechanism-based enzyme inactivation, in Chemistry and Enzymology, vol 1 pp 3-16, CRC Press Inc, Florida.
26. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
27. Tran JQ, Petersen C, Garrett M, Hee B, and Kerr BM (2002) Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther 72:615-626.
28. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res (NY) 18:1071-1080.
29. Walgren JL, Mitchell MD, and Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35:325-361.
30. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
31. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
32. Yamamoto T, Suzuki A, and Kohno Y (2004) High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 34:87-101.
33. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.
34. Zhao P, Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861.
35. Zhou S, Chan E, Duan W, Huang M, and Chen YZ (2005a) Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 37:41-213.
36. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, and Huang M, Xu A (2004) Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415-442.
37. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, and McLeod HL (2005b) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.